Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Director Andreas Wicki sold 14,527 shares of the business’s stock in a transaction dated Thursday, December 13th. The shares were sold at an average price of $46.84, for a total value of $680,444.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Andreas Wicki also recently made the following trade(s):

  • On Friday, November 16th, Andreas Wicki sold 70,498 shares of Pacira Pharmaceuticals stock. The shares were sold at an average price of $47.34, for a total value of $3,337,375.32.
  • On Monday, November 12th, Andreas Wicki sold 5,478 shares of Pacira Pharmaceuticals stock. The shares were sold at an average price of $49.83, for a total value of $272,968.74.
  • On Friday, November 9th, Andreas Wicki sold 58,245 shares of Pacira Pharmaceuticals stock. The shares were sold at an average price of $51.11, for a total value of $2,976,901.95.

NASDAQ:PCRX opened at $45.26 on Friday. Pacira Pharmaceuticals Inc has a 12 month low of $26.95 and a 12 month high of $55.00. The company has a quick ratio of 7.83, a current ratio of 8.66 and a debt-to-equity ratio of 0.95. The company has a market cap of $1.86 billion, a price-to-earnings ratio of 251.44 and a beta of 1.65.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings data on Thursday, November 1st. The company reported $0.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.40. Pacira Pharmaceuticals had a positive return on equity of 2.74% and a negative net margin of 1.30%. The company had revenue of $83.45 million during the quarter, compared to analyst estimates of $79.87 million. During the same period in the previous year, the business earned $0.11 EPS. Pacira Pharmaceuticals’s quarterly revenue was up 23.9% on a year-over-year basis.

Large investors have recently bought and sold shares of the business. Bouchey Financial Group Ltd purchased a new stake in Pacira Pharmaceuticals during the 3rd quarter worth approximately $221,000. Boston Private Wealth LLC purchased a new stake in Pacira Pharmaceuticals during the 3rd quarter worth approximately $246,000. First Republic Investment Management Inc. purchased a new stake in Pacira Pharmaceuticals during the 3rd quarter worth approximately $258,000. Parametrica Management Ltd purchased a new stake in Pacira Pharmaceuticals during the 3rd quarter worth approximately $259,000. Finally, Baird Financial Group Inc. purchased a new stake in Pacira Pharmaceuticals during the 3rd quarter worth approximately $288,000. Institutional investors own 97.84% of the company’s stock.

Several equities analysts have recently issued reports on PCRX shares. Needham & Company LLC set a $60.00 price objective on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, November 1st. ValuEngine lowered Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 2nd. Piper Jaffray Companies set a $55.00 price target on Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 1st. Canaccord Genuity set a $45.00 price target on Pacira Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, September 4th. Finally, HC Wainwright lifted their price target on Pacira Pharmaceuticals to $60.00 and gave the company a “buy” rating in a research note on Friday, November 2nd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $53.76.

WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2018/12/16/andreas-wicki-sells-14527-shares-of-pacira-pharmaceuticals-inc-pcrx-stock.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

See Also: Call Option

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.